

Clinical trials Celltrion 12/11/2015 (<https://clinicaltrials.gov>)

No.	Study	Status	Phase	Estimated Enrollment	Study Start Date/ Estimated Study Completion Date
1.	Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial	Terminated	Phase 1	1	02.2012/ 02.2013
2.	Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis	Completed	Phase 1	154	02.2012/ 02.2014
3.	Long-Term Efficacy and Safety of CT-P10 in Patients With RA	Active, not recruiting	Phase 1	102	05.2013/ 12.2015
4.	PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis	Active, not recruiting	Phase 3	300	05.2014/ 07.2017
5.	To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan	Recruiting	Phase 3	250	06.2014/ 06.2020
6.	To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma	Not yet recruiting	Phase 3	104	10.2015/ 08.2020